Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TR-701 Dose-Ranging Study in cSSSI
NCT00761215Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2008
- Primary completion
- Feb 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tedizolid in Skin and Skin Structure Infection (SSSI), sponsored by Merck & Co.. Started Sep 2008; status: completed.
02
Drugs
tedizolid
03
Conditions
Skin and Skin Structure Infection (SSSI)
Beyond the preview
Go deeper on NCT00761215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00761215.